Pfizer plans to seek emergency use authorization from the Food and Drug Administration for its COVID-19 vaccine candidate Friday, the company and its partner BioNTech announced Wednesday night. Pfizer said a final analysis of its coronavirus vaccine candidate's phase three trial showed that it was 95 percent effective, as of the 170 coronavirus cases reported in the trial, only eight were among those who received the vaccine. Pfizer and BioNTech also said "efficacy was consistent across age, race, and ethnicity demographics," and the "observed efficacy in adults over 65 years of age was over 94 percent." Pfizer said there have not been "any serious safety concerns related to the vaccine" reported. On Monday, drug maker Moderna also announced that preliminary phase-three trial data showed its coronavirus vaccine candidate was more than 94 percent effective.

Scroll for 5 things you
need to know now